Better guidelines for better care: accounting for multimorbidity in clinical guidelines – structured examination of exemplar guidelines and health economic modelling

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Health Services and Delivery Research

• Publication date

  2017-04-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.3310/HSDR05160
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Using the Payoff Time in Decision-Analytic Models: A Case Study for Using Statins in Primary Prevention

  2017cited by this paper
• Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial

  2015cited by this paper
• Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury.

  2015cited by this paper
• Quantifying the Utility of Taking Pills for Cardiovascular Prevention

  2015cited by this paper
• Integrated primary care for patients with mental and physical multimorbidity: cluster randomised controlled trial of collaborative care for patients with depression comorbid with diabetes or cardiovascular disease

  2015cited by this paper
• Changes in opioid and other analgesic use 1995–2010: Repeated cross‐sectional analysis of dispensed prescribing for a large geographical population in Scotland

  2015cited by this paper
• Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines

  2015cited by this paper
• The Influence of Cost-Effectiveness and Other Factors on Nice Decisions.

  2015cited by this paper
• Quantifying the utility of taking pills for preventing adverse health outcomes: a cross-sectional survey

  2015cited by this paper
• What to give the patient who has everything? A qualitative study of prescribing for multimorbidity in primary care.

  2015cited by this paper
• The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010

  2015cited by this paper
• Patient-Accessible Tool for Shared Decision Making in Cardiovascular Primary Prevention: Balancing Longevity Benefits Against Medication Disutility

  2014cited by this paper
• Core discrete event simulation model for the evaluation of health care technologies in major depressive disorder.

  2014cited by this paper
• Stroke, multimorbidity and polypharmacy in a nationally representative sample of 1,424,378 patients in Scotland: implications for treatment burden

  2014cited by this paper
• The influence of socioeconomic deprivation on multimorbidity at different ages: a cross-sectional study

  2014cited by this paper
• Lag time to benefit for preventive therapies.

  2014cited by this paper
• Understanding adverse drug reactions in older adults through drug-drug interactions.

  2014cited by this paper
• Unhelpful information about adverse drug reactions

  2014cited by this paper
• Including Adverse Drug Events in Economic Evaluations of Anti-Tumour Necrosis Factor-α Drugs for Adult Rheumatoid Arthritis: A Systematic Review of Economic Decision Analytic Models

  2014cited by this paper
• Predicting survival in heart failure: validation of the MAGGIC heart failure risk score in 51 043 patients from the Swedish Heart Failure Registry

  2014cited by this paper
• Prevalence, Determinants and Patterns of Multimorbidity in Primary Care: A Systematic Review of Observational Studies

  2014cited by this paper
• Using the Coronary Artery Calcium Score to Guide Statin Therapy: A Cost-Effectiveness Analysis

  2014cited by this paper
• USE OF VALUE OF INFORMATION IN UK HEALTH TECHNOLOGY ASSESSMENTS

  2014cited by this paper
• The ‘everyday work’ of living with multimorbidity in socioeconomically deprived areas of Scotland

  2014cited by this paper
• Potential Therapeutic Competition in Community-Living Older Adults in the U.S.: Use of Medications That May Adversely Affect a Coexisting Condition

  2014cited by this paper
• Multimorbidity patterns: a systematic review.

  2014cited by this paper
• Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies?

  2014cited by this paper
• Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study

  2014cited by this paper
• A Framework for Crafting Clinical Practice Guidelines that are Relevant to the Care and Management of People with Multimorbidity

  2014cited by this paper
• A web-based tool for eliciting probability distributions from experts

  2014cited by this paper
• The effect of physical multimorbidity, mental health conditions and socioeconomic deprivation on unplanned admissions to hospital: a retrospective cohort study

  2013cited by this paper
• Applying the Payoff Time Framework to Carotid Artery Disease Management

  2013cited by this paper
• Do participants in major, practice-changing breast cancer trials reflect the breast cancer patient population?

  2013cited by this paper
• Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project.

  2013cited by this paper
• Implementing GRADE: calculating the risk difference from the baseline risk and the relative risk

  2013cited by this paper
• Implications of comorbidity for primary care costs in the UK: a retrospective observational study.

  2013cited by this paper
• Introducing GRADE across the NICE clinical guideline program.

  2013cited by this paper
• Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation in Turkey: A Microsimulation Approach.

  2013cited by this paper
• External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants?

  2013cited by this paper
• GPs’ perspectives on the management of patients with multimorbidity: systematic review and synthesis of qualitative research

  2013cited by this paper
• Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidity.

  2013cited by this paper
• Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies.

  2013cited by this paper
• Rationalizing Prescribing for Older Patients with Multimorbidity: Considering Time to Benefit

  2013cited by this paper
• Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help?

  2013cited by this paper
• Double trouble: the impact of multimorbidity and deprivation on preference-weighted health related quality of life a cross sectional analysis of the Scottish Health Survey

  2013cited by this paper
• Estimating Health State Utility Values for Joint Health Conditions

  2013cited by this paper
• Adapting clinical guidelines to take account of multimorbidity

  2012cited by this paper
• Estimating benefits and harms of screening across subgroups: the Canadian Task Force on Preventive Health Care integrates the GRADE approach and overcomes minor challenges.

  2012cited by this paper
• A proposed model for economic evaluations of major depressive disorder

  2012cited by this paper
• A Critical Review of Model-Based Economic Studies of Depression

  2012cited by this paper
• Rationale and methodology for trial-based economic evaluation

  2012cited by this paper
• Subgroups and Heterogeneity in Cost-Effectiveness Analysis

  2012cited by this paper
• Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study.

  2012cited by this paper
• Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review

  2012cited by this paper
• Uncertainties in baseline risk estimates and confidence in treatment effects

  2012cited by this paper
• Collaborative Interventions for Circulation and Depression (COINCIDE): study protocol for a cluster randomized controlled trial of collaborative care for depression in people with diabetes and/or coronary heart disease

  2012cited by this paper
• Pharmacoeconomic analyses using discrete event simulation

  2012cited by this paper
• Why and how do elderly patients with heart failure die? Insights from the TIME‐CHF study

  2012cited by this paper
• Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment

  2012cited by this paper
• How to integrate multiple comorbidities in guideline development: article 10 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report.

  2012cited by this paper
• The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

  2012cited by this paper
• Time lag to benefit after screening for breast and colorectal cancer: meta-analysis of survival data from the United States, Sweden, United Kingdom, and Denmark

  2012cited by this paper
• Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2.

  2012cited by this paper
• GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables.

  2011cited by this paper
• Current Guidelines Have Limited Applicability to Patients with Comorbid Conditions: A Systematic Analysis of Evidence-Based Guidelines

  2011cited by this paper
• Cost-Effectiveness of Statin Therapy for Primary Prevention in a Low-Cost Statin Era

  2011cited by this paper
• Canadian guidelines for clinical practice: an analysis of their quality and relevance to the care of adults with comorbidity

  2011cited by this paper
• Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis

  2011cited by this paper
• Prevalence and outcomes of use of potentially inappropriate medicines in older people: cohort study stratified by residence in nursing home or in the community

  2011cited by this paper
• Epidemiology and impact of multimorbidity in primary care: a retrospective cohort study.

  2011cited by this paper
• GRADE guidelines: 8. Rating the quality of evidence--indirectness.

  2011cited by this paper
• High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice

  2011cited by this paper
• Can Life Expectancy and QALYs Be Improved by a Framework for Deciding Whether to Apply Clinical Guidelines to Patients With Severe Comorbid Disease?

  2011cited by this paper
• An ‘endless struggle’: a qualitative study of general practitioners’ and practice nurses’ experiences of managing multimorbidity in socio-economically deprived areas of Scotland

  2011cited by this paper
• Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction

  2011cited by this paper
• National Clinical Guideline Centre Cost-Effectiveness Assessment for the National Institute for Health and Clinical Excellence

  2011cited by this paper
• Simplicity, Complexity and Modelling: Christie/Simplicity, Complexity and Modelling

  2011cited by this paper
• Adverse drug events in the outpatient setting: an 11‐year national analysis

  2010cited by this paper
• Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus.

  2010cited by this paper
• Collaborative care for patients with depression and chronic illnesses.

  2010cited by this paper
• Systematic reviews of economic evaluations: utility or futility?

  2010cited by this paper
• Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis.

  2010cited by this paper
• Increasing polypharmacy - an individual-based study of the Swedish population 2005-2008

  2010cited by this paper
• Managing medications in clinically complex elders: "There's got to be a happy medium".

  2010cited by this paper
• Common problems related to the use of number needed to treat.

  2010cited by this paper
• Discrete event simulation: the preferred technique for health economic evaluations?

  2010cited by this paper
• Co-morbidity: we need a guideline for each patient not a guideline for each disease.

  2010cited by this paper
• Comparing Impact and Cost-Effectiveness of Primary Prevention Strategies for Lipid-Lowering

  2009cited by this paper
• We need minimally disruptive medicine

  2009cited by this paper
• Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.

  2009cited by this paper
• Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report.

  2009cited by this paper
• Are adverse effects incorporated in economic models? An initial review of current practice.

  2009cited by this paper
• Defining Comorbidity: Implications for Understanding Health and Health Services

  2009cited by this paper
• The use of QALYs in clinical and patient decision-making: issues and prospects.

  2009cited by this paper
• The Payoff Time: A Flexible Framework to Help Clinicians Decide When Patients With Comorbid Disease are not Likely to Benefit From Practice Guidelines

  2009cited by this paper
• GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

  2008cited by this paper
• Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.

  2008cited by this paper
• The “number needed to treat” turns 20 — and continues to be used and misused

  2008cited by this paper
• Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2

  2008cited by this paper
• BMC Medical Informatics and Decision Making

  2008cited by this paper

• Making clinical guidelines work for people with multiple long term conditions: analysis and recommendations from review of single condition guidelines.

  2026cites this paper
• Rethinking care for multiple long term conditions: beyond guidelines for single diseases.

  2026cites this paper
• Clinical decision-making and care pathways for people with multiple long-term conditions admitted to hospital: a scoping review

  2025cites this paper
• Service innovations for people with multiple long-term conditions: reflections of a rapid evaluation team.

  2024cites this paper
• Assessment of adherence to therapy and options for polypharmacy in patients with CHF according to local registry data

  2024cites this paper
• Best practice for the selection, design and implementation of UK Kidney Association guidelines: a modified Delphi consensus approach

  2024cites this paper
• The implications of competing risks and direct treatment disutility in cardiovascular disease and osteoporotic fracture: risk prediction and cost effectiveness analysis.

  2024cites this paper
• Quantifying the impact of taking medicines for primary prevention: a time-trade off study to elicit direct treatment disutility in the UK

  2023cites this paper
• Assessing treatment effect modification due to comorbidity using individual participant data from industry-sponsored drug trials

  2023cites this paper
• A Digital Tool for Clinical Evidence–Driven Guideline Development by Studying Properties of Trial Eligible and Ineligible Populations: Development and Usability Study

  2023cites this paper
• Treatment effect modification due to comorbidity: Individual participant data meta-analyses of 120 randomised controlled trials

  2023cites this paper
• How can we fund research for people, not conditions?

  2022cites this paper
• Using Economic Evaluation to Inform Responses to the Opioid Epidemic in the United States: Challenges and Suggestions for Future Research

  2022influential citation
• Concept of the Number Needed to Treat for the Analysis of Pain Relief Outcomes in Patients Treated with Spinal Cord Stimulation

  2022cites this paper
• Prevalence of polypharmacy in community-dwelling older adults from seven centres in five European countries: a cross-sectional study of DO-HEALTH

  2022cites this paper
• Revising the Suspected-Cancer Guidelines: Impacts on Patients' Primary Care Contacts and Costs.

  2022cites this paper
• Predictors and outcomes in primary depression care (POKAL) – a research training group develops an innovative approach to collaborative care

  2022cites this paper
• The Prevalence of Potentially Inappropriate Prescribing in the Elderly at the Primary Care Level in Kazakhstan

  2021cites this paper
• How common are Chinese patients with multimorbidity involved in decision‐making and having a treatment plan? A cross‐sectional study

  2021cites this paper
• Guidelines for hypertension management in primary care: is local adaptation possible?

  2020cites this paper
• Exclusion rates in randomized controlled trials of treatments for physical conditions: a systematic review

  2020cites this paper
• Assessment of Whether the American Society of Clinical Oncology's Value Framework and the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale Measure Absolute or Relative Clinical Survival Benefit: A Meta-analysis of Randomized Clinical Trials.

  2019cites this paper
• GPs' management of polypharmacy and therapeutic dilemma in patients with multimorbidity: a cross-sectional survey of GPs in France.

  2019cites this paper
• How common are Chinese patients with multimorbidity involved in decision making and having a treatment plan? a cross-sectional study

  2019cites this paper
• Pre-operative optimisation of the surgical patient with diagnosed and undiagnosed diabetes

  2019cites this paper
• Modeling the Economic Impact of Interventions for Older Populations with Multimorbidity: A Method of Linking Multiple Single-Disease Models

  2019cites this paper
• Estimating Joint Health Condition Utility Values.

  2019cites this paper
• Pre‐operative optimisation of the surgical patient with diagnosed and undiagnosed diabetes: a practical review

  2019cites this paper
• Interpreting clinical guidelines

  2018cites this paper
• Search for decompensation risk factors within the EGPRN multimorbidity’s definition themes. Cohort pilot study, follow up at 18 months in nursing home

  2017cites this paper